可可黄素通过在健康老年人随机双盲试验中减少左心房体积来缓解早期的透析功能障碍
Dragos Andrei Duse1, Michael Gröne1, Niklas Ophoff1
1Department of Cardiology, Pulmonology and Angiology Medical Faculty, Heinrich Heine University of Duesseldorf, Duesseldorf, Germany. ralf.erkens@med.uni-duesseldorf.de.
Food & function
|October 27, 2025
概括
在可可中发现的食类黄醇显著减少了健康老年人左心房和左心室的体积. 这表明,黄醇可以抵消早期的心脏功能障碍和重塑,为心血管提供好处.
科学领域:
- 心脏病学 心脏病学
- 营养科学 营养科学
- 老年学是指老年学的学科.
背景情况:
- 左心房 (LA) 扩大是心脏填充受损的标志物,也是心血管事件的预测因素.
- 饮食中的黄醇与心血管死亡率的降低有关,但其机制尚不清楚.
- 这项研究调查了醇对健康老年人心脏结构的影响.
研究的目的:
- 为了确定可可黄的摄入是否减少左心房 (LA) 容量在没有心血管疾病的老年人.
- 为了研究黄醇对心脏体积和透气功能的影响.
- 探索饮食中的黄醇对心血管的益处的机制.
主要方法:
- 一个随机双盲试验 (NCT05782309) 的副研究,涉及健康的老年人 (≥55岁).
- 参与者接受了500毫克的可可黄 (80毫克 (-) -epicatechin) 或对照剂,每天两次,持续30天.
- 心脏磁共振成像用于测量左心房 (LA) 和左心室 (LV) 的体积和应变率.
主要成果:
- 黄醇的摄入导致最大LA体积 (12.6%) 和LA体积指数显著降低.
- 观察到LV终端透析体积 (LVEDV) (4.4%) 和其指数显著减少.
- 缩血压在黄醇组下降了7mmHg (4.7%);菌株参数没有受到影响.
结论:
- 可可黄的摄入量通过逆转左心房和左心室的重塑来缓解早期的透析功能障碍.
- 这些发现为弗拉凡诺消费对心血管的益处提供了新的见解.
- 黄醇可能是预防老年人群心脏功能障碍的饮食干预.
相关概念视频
Coronary Artery Disease IV: Preventive Measures
580
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
580
Pharmacodynamics in Geriatric Patients: Effects of Age
183
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
183
Heart Failure II: Pathophysiology
704
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
704
Coronary Artery Disease III: Clinical Manifestations
317
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
317
Coronary Artery Disease II: Pathophysiology
360
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
360
Antihypertensive Drugs: Vasodilators
2.0K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.0K


